• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    7/6/23 1:37:23 PM ET
    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Caribou Biosciences (NASDAQ:CRBU) stock rose 50.7% to $6.15 during Thursday's regular session. The current volume of 75.4 million shares is 9750.6% of Caribou Biosciences's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $377.3 million.
    • Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 26.08% to $0.43. Aethlon Medical's stock is trading at a volume of 6.0 million shares as of 13:37 EST. This is 647.1% of its average full-day volume over the last 100 days. The company's market cap stands at $10.6 million.
    • Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 16.93% to $2.17. As of 13:37 EST, this security is trading at a volume of 6.2 million shares, making up 162555.0% of its average full-day volume over the last 100 days. The company's market cap stands at $138.0 million.
    • Myomo (AMEX:MYO) stock rose 16.14% to $0.72. Trading volume for this security as of 13:37 EST is 1.8 million, which is 555.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.0 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock increased by 15.7% to $5.01. Kintara Therapeutics's stock is trading at a volume of 171.4K shares as of 13:37 EST. This is 95.3% of its average full-day volume over the last 100 days. The company's market cap stands at $8.4 million.
    • C4 Therapeutics (NASDAQ:CCCC) stock rose 12.04% to $3.72. Trading volume for this security as of 13:37 EST is 4.7 million, which is 418.7% of its average full-day volume over the last 100 days. The company's market cap stands at $182.5 million.

    Losers

    • Allarity Therapeutics (NASDAQ:ALLR) shares fell 54.1% to $3.8 during Thursday's regular session. Trading volume for this security as of 13:37 EST is 2.5 million, which is 868.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.9 million.
    • Trinity Biotech (NASDAQ:TRIB) shares decreased by 27.07% to $0.78. Trinity Biotech's stock is trading at a volume of 585.7K shares as of 13:37 EST. This is 1442.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.9 million. The company's, Q1 earnings came out today.
    • ASLAN Pharma (NASDAQ:ASLN) shares fell 22.71% to $2.94. ASLAN Pharma's stock is trading at a volume of 3.0 million shares as of 13:37 EST. This is 3826.8% of its average full-day volume over the last 100 days. The company's market cap stands at $48.1 million.
    • Nymox Pharmaceutical (NASDAQ:NYMX) shares declined by 19.64% to $0.2. Trading volume for Nymox Pharmaceutical's stock is 633.6K as of 13:37 EST. This is 529.5% of its average full-day volume over the last 100 days. The company's market cap stands at $18.2 million.
    • ALX Oncology Holdings (NASDAQ:ALXO) stock fell 16.74% to $6.07. The current volume of 437.6K shares is 149.5% of ALX Oncology Holdings's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $248.0 million.
    • Comera Life Sciences (NASDAQ:CMRA) shares decreased by 15.77% to $0.49. The current volume of 114.5K shares is 204.3% of Comera Life Sciences's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $10.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ALLR
    $ALXO
    $ASLN

    CompanyDatePrice TargetRatingAnalyst
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    C4 Therapeutics Inc.
    $CCCC
    12/2/2025Buy
    TD Cowen
    ALX Oncology Holdings Inc.
    $ALXO
    11/13/2025$4.00Buy
    Jefferies
    C4 Therapeutics Inc.
    $CCCC
    9/17/2025$8.00Overweight
    Barclays
    C4 Therapeutics Inc.
    $CCCC
    9/15/2025$6.00Equal-Weight → Overweight
    Stephens
    C4 Therapeutics Inc.
    $CCCC
    9/4/2025$8.00Buy
    Guggenheim
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    More analyst ratings

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

     - Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization   - Anticipating initiation of pivotal clinical trial in 2026   - Updated electronics architecture delivers significant improvement in glucose measurement accuracy, with a material reduction in MARD across multi-day wear   - Multimodal sensing platform powered by advanced AI-native analytics to deliver personalized metabolic health insights   - CGM+ next-generation modular device architecture designed to reduce cost and improve sustainability versus current market-leading CGMs  - Company is positioning device to participate in fast-growing $15bn CGM market and adjacent sector

    3/10/26 7:55:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Provides Business and Trading Update

    DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an update on its trading activities for Quarter 4, 2025 and some key business updates. Trading Update The Company expects Quarter 4, 2025 revenue within the range of approximately $11.5 million to $12.5 million.This compares to Quarter 4, 2024 revenue of $15.9 million, which was driven by a substantial increase in TrinScreen™ HIV sales from $0.4 million in Quarter 4, 2023 to $3.2 million in Quarter 4, 2024.The reduction in revenue between Quarter 4, 2024 and Qua

    3/10/26 7:45:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on C4 Therapeutics

    TD Cowen initiated coverage of C4 Therapeutics with a rating of Buy

    12/2/25 8:23:26 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on ALX Oncology with a new price target

    Jefferies initiated coverage of ALX Oncology with a rating of Buy and set a new price target of $4.00

    11/13/25 9:09:54 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Crowley Thomas Aloysius Jr. bought $3,233 worth of shares (4,385 units at $0.74), increasing direct ownership by 6% to 75,748 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/21/25 7:22:22 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Klencke Barbara

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:05:06 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Klencke Barbara claimed ownership of 120,000 shares (SEC Form 3)

    3 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:01:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/27/26 4:01:13 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    SEC Filings

    View All

    SEC Form 424B3 filed by Trinity Biotech plc

    424B3 - TRINITY BIOTECH PLC (0000888721) (Filer)

    3/10/26 8:10:05 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B3 filed by Trinity Biotech plc

    424B3 - TRINITY BIOTECH PLC (0000888721) (Filer)

    3/10/26 8:07:48 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by Trinity Biotech plc

    6-K - TRINITY BIOTECH PLC (0000888721) (Filer)

    3/10/26 8:01:53 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

    Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Profile That May Be Ideal for Combination Regimens C4T to Pursue Differentiated Development Strategy With Two Distinct Opportunities for Accelerated Approval in Second Line and Later C4T to Host Webc

    9/20/25 11:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Provides Business and Trading Update

    DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an update on its trading activities for Quarter 4, 2025 and some key business updates. Trading Update The Company expects Quarter 4, 2025 revenue within the range of approximately $11.5 million to $12.5 million.This compares to Quarter 4, 2024 revenue of $15.9 million, which was driven by a substantial increase in TrinScreen™ HIV sales from $0.4 million in Quarter 4, 2023 to $3.2 million in Quarter 4, 2024.The reduction in revenue between Quarter 4, 2024 and Qua

    3/10/26 7:45:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $AEMD
    $ALLR
    $ALXO
    $ASLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

    SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    12/6/24 4:06:56 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    11/14/24 7:53:54 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care